Paradoxical oncogenesis: Are all BRAF inhibitors equal?

Alexander M. Menzies*, Richard F. Kefford, Georgina V. Long

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

44 Citations (Scopus)

Abstract

Summary: Cutaneous squamous cell carcinoma (cSCC) is a concerning toxicity with BRAF inhibitors in the treatment for melanoma. While the two drugs shown to improve survival, vemurafenib, and dabrafenib, have similar efficacy, the reported rates of cSCC are quite different. Drawing upon preclinical and clinical trial data, this article discusses the potential factors behind the different cSCC incidences reported with the two BRAF inhibitors and provides a strategic approach to understand this issue further.

Original languageEnglish
Pages (from-to)611-615
Number of pages5
JournalPigment Cell and Melanoma Research
Volume26
Issue number5
DOIs
Publication statusPublished - Sept 2013
Externally publishedYes

Fingerprint

Dive into the research topics of 'Paradoxical oncogenesis: Are all BRAF inhibitors equal?'. Together they form a unique fingerprint.

Cite this